Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers

MLA

Pamela S. Douglas, et al. “Rationale and Design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers.” American Heart Journal, vol. 212, June 2019, pp. 1–12. EBSCOhost, https://doi.org/10.1016/j.ahj.2019.02.011.

APA

Pamela S. Douglas, Beverly Alston-Smith, Myron A. Waclawiw, Udo Hoffmann, Markella V. Zanni, Michael T. Lu, John Sukumar Aluru, Patrice Desvigne-Nickens, Devvora Olalere, Steven K. Grinspoon, Heather J. Ribaudo, Karin L. Klingman, Elizabeth C. Adami, Saeyun Lee, Tricia H. Burdo, Reprieve Investigators, Katharine Cooper-Arnold, Kathleen V. Fitch, Nadja Arifovic, … Michael T. Osborne. (2019). Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. American Heart Journal, 212, 1–12. https://doi.org/10.1016/j.ahj.2019.02.011

Chicago

Pamela S. Douglas, Beverly Alston-Smith, Myron A. Waclawiw, Udo Hoffmann, Markella V. Zanni, Michael T. Lu, John Sukumar Aluru, et al. 2019. “Rationale and Design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers.” American Heart Journal 212 (June): 1–12. doi:10.1016/j.ahj.2019.02.011.